The Future of MDMA: Phase 3 and Beyond

Russell Hausfeld
What does the future hold for MDMA? We explore MAPS' ongoing FDA phase 3 clinical trials, rescheduling, health insurance, and expanded access. 

It’s time to debunk prohibitionist narratives and calls for monopolies within psychedelic science

David Nickles
October 25, 2018
As venture-capital-backed, for-profit companies barrel into psychedelic therapy, the potential for the widespread privatization of psychedelic knowledge and profits looms large. Some researchers are so enthusiastic about medicalization by “any means necessary” that they’re resorting to prohibitionist historical narratives and calling for monopolies to push the agenda forward.

Becoming a Psychedelic Researcher: Alan Kooi Davis

Russell Hausfeld
April 25, 2018
Why researchers like Alan Kooi Davis — the newest addition to the Johns Hopkins psychedelic research team — decide to devote their careers to studying psychedelics.

The State: The Opioid Epidemic

Emerson Dameron
November 14, 2017
For anyone who remembers the Reagan Administration's awesome response to the '80s crack epidemic, the Trump plan may prompt discouraging deja vu.

A day in the life of a consultant psychiatrist and psychedelic drug researcher

Ben Sessa
November 6, 2017
I work with children whom have used drugs before incarceration to have fun. I also work in an adult addictions service with people whose drug use is mistaken for the cause of their problems. My patients are simply self-medicating. Nevertheless, I give them my drugs and help them off theirs.

Your Brain on Psychedelic Drugs

Marlene Rupp
November 2, 2017
What is it about psychedelics that has the power to change lives for the better? The answer might lie in the unique ways that psychedelics interact with the brain.

The State: Friday, Oct 27, 2017

Emerson Dameron
October 27, 2017
To get a vision of the future of psychedelics from a legal and regulatory perspective, the most useful thing to do might be to see what's happening already in the realm of weed.

Psychedelics and Mental Health

Marlene Rupp
October 25, 2017
Depression. Anxiety. Addiction. Most everyone of us knows somebody who is battling such a condition. Talk therapies may help, but sometimes they don’t. Antidepressants may help, but sometimes they don’t. Some patients are of the opinion that antidepressants are like “Band-Aids” in the way that they never really tackle the underlying issues of their problems.

The State: Tuesday, Sept 19, 2017

Emerson Dameron
September 19, 2017
Welcome to the first edition of The State. This column will look at a few of the more noteworthy stories making waves in the psychedelic and reform spheres, and when appropriate, examine how they fit into a larger context.

Of Molecules and Minds: The Science of Ayahuasca

Thomas Varley
August 16, 2017
There’s a beauty and sense of wonder that comes from knowing how the world works, and the nature of the psychedelic experience dovetails almost perfectly with that awareness.

Precautions with Underground Psychedelic Therapy

Brenda Brewer
March 9, 2017
In underground sessions, you’re taking a huge risk choosing to work with someone who may not have adequately prepared or may have dubious subconscious motivations.

Non-PTSD Uses for MDMA

Josh Dietz
January 26, 2017
MDMA has the potential of treating and reversing even the most pervasive of pathologies in the mental health world

The Psychonaut’s Dilemma

Albert Garcia-Romeu
May 31, 2016
During an earlier era of psychedelic research, the 1950s-70s, some scientists believed that in order to ethically administer psychedelics to others it was necessary to first experience them oneself.